TARS news

Tarsus reported Q2 2026 net product sales of $173.9 million for XDEMVY and updated full-year guidance to $685-705 million, while advancing a pending acquisition of Alkeus Pharmaceuticals.

Tarsus Pharmaceuticals, Inc. issued a pre-funded warrant to purchase up to a total of shares of common stock with an exercise price of $0.0001. The warrant is part of a series issued pursuant to a Securities Purchase Agreement dated August 5, 2026.

Tarsus Pharmaceuticals will acquire Alkeus Pharmaceuticals to obtain gildeuretinol, a Phase 3 oral therapy for Stargardt disease, a leading inherited retinal disease with no FDA-approved treatment.